ASPIAG, s.r.o

What ASPIAG, s.r.o does

ASPIAG, s.r.o. is a privately held, family-owned Czech software company founded in 2005 and headquartered in Litomyšl. It designs and develops software for infection diagnostic laboratories, centered on the BACMED 6iG2 platform. The company is operated by a small principal team: a Science Advisor who is an infection-disease physician, a Systems Architect responsible for software development, and an Account Manager who also functions as executive manager and economist. No external investors, parent company, or M&A activity are disclosed.

The BACMED 6iG2 platform integrates three modules into a single microbiology software suite. The Automated AST reader and analyser uses an 18 megapixel APS-C CMOS sensor with 0.05 mm vector precision in under 50 milliseconds, supports EUCAST, CLSI, or custom breakpoint sets, and calculates MIC values using a method approved under US-FDA 510(k) and British BSAC control procedures. The Equation builder based expert system (Sentinel) performs automated phenotype detection and re-interpretation during measurement according to locally configurable rules. The Epidemiology expert system creates AST susceptibility fingerprints for bacterial strains and tracks potential patient-to-patient or department-to-department transfers, with disclosed validation of over 85% detection across 3,000 samples and match marking of 1,000 samples in under one minute. An additional In-Depth Expert Analysis (IDEA) service positions the platform for downstream hospital and healthcare facility customers.

ASPIAG sells exclusively through direct sales, with no public pricing, channel partners, or distribution agreements disclosed. Customer-facing assets are limited to the company's Czech and English website, downloadable product sheets, and direct contact with the account manager. The company operates in a single identifiable segment — infection diagnostic laboratories — with a secondary go-to-market layer into hospitals via the IDEA service. No revenue, headcount, or installed-base figures are publicly available.

Name

ASPIAG, s.r.o

Legal name

ASPIAG s.r.o.

Website

https://aspiag.cz

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

11–50 employees

Short description

ASPIAG, s.r.o. is a Czech family-owned software company that develops the BACMED 6iG2 platform for infection diagnostic laboratories, providing automated AST reading, expert system-based phenotype detection, and epidemiology tracking for bacterial strain transfers.

Ownership category

akta.pro rank

Product category

Microbiology Laboratory Software

NAICS

Analytical Laboratory Instrument Manufacturing (334516), Software Publishers (513210)

SIC

Laboratory Analytical Instruments (3826), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO)

akta.pro secondary industries

Quality, Compliance & Validation Software for Labs (GxP/CSV, eQMS for QC Labs) (HLAGAJAI), Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL)

Keywords

• Microbiology lab software
• Antimicrobial susceptibility testing
• Infection diagnostic software
• Epidemiology tracking systems
• Laboratory information systems

Headquarters

HQ city

Litomyšl

HQ country

Czechia

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Distribution channels1 record

Marketing channels2 records

Core offering

ASPIAG designs and develops the BACMED 6iG2 software platform for infection diagnostic laboratories. The integrated platform combines three modules: an automated AST (Antimicrobial Susceptibility Testing) reader and analyser for zone measurement and MIC calculation, an equation builder-based expert system for phenotype detection, and an epidemiology expert system that tracks bacterial strain transfers between patients, departments, and healthcare facilities. The software processes AST susceptibility data to generate surveillance statistics, antibacterial resistance reports, and trend analysis for bacteriology and epidemiology applications.

Product overview

ASPIAG, s.r.o. is a Czech family-owned company established in 2005 that designs and develops software for infection diagnostic laboratories. Their product portfolio centers on BACMED® 6iG2, a comprehensive microbiology software platform comprising three integrated modules: the Automated AST reader and analyser (for zone measurement and MIC calculation), the Equation builder based expert system (for phenotype detection and automated result interpretation), and the Epidemiology expert system (for strain tracking and patient transfer detection). The platform processes AST susceptibility data to generate surveillance statistics, antibacterial resistance reports, and trend analysis for bacteriology and epidemiology applications.

Differentiator

Problem solved

Functional benefit

Brands

• BACMED 6iG2: Main product suite for infection diagnostic laboratories, including automated AST reader and analyser, equation builder based expert system, and epidemiology expert system.

Products and services

• BACMED 6iG2 Comprehensive software platform for infection diagnostic laboratories integrating three modules: Automated AST reader and analyser, Equation builder based expert system, and Epidemiology expert system. Supports antimicrobial susceptibility testing, surveillance statistics, bacteriology and epidemiology analysis for clinical microbiology labs.
• Automated AST Reader and Analyser Module for quick and precise measurement of inhibitory zones in antimicrobial susceptibility testing. Features an 18 Megapixel APS-C CMOS sensor, 2D barcode reader (Data Matrix), LED field illumination, and 0.05 mm precision vector analysis in under 50 milliseconds. Supports EUCAST, CLSI or custom breakpoint sets with orientational MIC calculation.
• Equation Builder Based Expert System Expert system module for phenotype detection enabling real-time analysis during BACMED measuring. Performs phenotype-based interpretation including zone synergies and SIR combinations, with automated re-interpretation of irrelevant results to prevent treatment failure.
• Epidemiology Expert System Epidemiology module using AST susceptibility fingerprints to track bacterial strain transfers between patients, departments, or healthcare facilities. Creates match marking reports in under one minute for 1,000 samples. Includes the In-Depth Expert Analysis (IDEA) service for hospitals and healthcare facilities.

Quantifiable outcome

• Match marking of 1,000 samples requires below 1 minute of analysis, including side statistics
• +3 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature6 records

Scale indicators2 records

Recent moves3 records

Expansion highlights3 records

Direct peers

• bioMérieux: bioMérieux's VITEK 2 and VITEK MS systems are dominant integrated AST and microbial identification platforms sold to clinical microbiology labs. They directly compete with BACMED's AST reading and expert-interpretation functionality, with similar buyer profile and EUCAST/CLSI workflow.
• Copan Diagnostics: Copan offers the WaspTouch and Colibrí systems for automated AST disc reading and zone measurement, targeting the same clinical microbiology laboratory customers as ASPIAG. Its hardware-plus-software AST reading stack is the closest direct analog to the BACMED 6iG2 reader module.
• Liofilchem: Liofilchem produces antimicrobial susceptibility testing discs and instruments (e.g., the MIC Test Strip and associated readers) used in the same microbiology lab workflow that ASPIAG serves. The companies overlap in the AST disc-reading and interpretation value chain, particularly in European markets.
• Becton Dickinson (BD): BD's Phoenix M50 is a leading automated AST and ID system for clinical microbiology laboratories. It competes head-to-head with ASPIAG in the AST reading/interpretation workflow, with overlapping customers and a similar regulatory and standards landscape (CLSI, EUCAST).
• Beckman Coulter (Danaher): Beckman Coulter's MicroScan system is a long-established walkaway AST and identification platform used by hospital microbiology labs. It competes directly with BACMED on automated AST reading, breakpoint interpretation, and lab throughput value propositions.

Broad incumbents

• LabWare: LabWare is a leading LIMS vendor used by clinical and analytical laboratories. While broader than ASPIAG's specialist AST focus, LabWare competes for the same lab informatics budget and could absorb AST interpretation into a generalized LIMS workflow over time.
• Thermo Fisher Scientific: Thermo Fisher supplies a broad portfolio of laboratory instruments, reagents, and informatics that intersect with clinical microbiology workflows (e.g., Oxoid AST media, microbiology consumables, and lab informatics). As an incumbent it competes indirectly with BACMED via bundled offerings and LIS-adjacent tooling.
• Bruker: Bruker's MALDI Biotyper dominates microbial identification in clinical microbiology labs and increasingly intersects with AST workflow through downstream analysis software. It is a broad incumbent whose identification-and-analysis stack is a logical adjacency (and potential bundling competitor) to ASPIAG's AST-focused platform.

Emerging players

• Accelerate Diagnostics: Accelerate Diagnostics offers rapid phenotypic AST systems (e.g., the Accelerate Pheno system) that deliver AST results in hours rather than days, directly addressing the same antimicrobial susceptibility workflow as BACMED. They compete on speed and are a credible emerging alternative for innovation-forward labs.
• Q-Linea: Q-Linea's ASTar is an automated AST system that uses imaging and AI-driven analysis for rapid AST, directly paralleling ASPIAG's automated imaging, vector analysis, and algorithmic interpretation of inhibition zones. It targets the same clinical microbiology lab buyer.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/aspiag-s-r-o

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ASPIAG, s.r.o